Title: Apple Faces Potential Smartwatch Ban in the US due to Patent Dispute
Apple Inc. may face a ban on the sale of its Series 9 and Ultra 2 smartwatches in the United States due to a patent dispute with Masimo Corp. The dispute revolves around the technology that enables the blood oxygen feature on Apple's wearable devices. The US International Trade Commission (ITC) upheld a ruling that Apple had violated Masimo's rights in light-based technology for reading blood-oxygen levels. President Joe Biden's administration has 60 days to decide whether to veto the import ban before it goes into effect.
The blood oxygen feature, which monitors the level of oxygen in the blood throughout the day, was first introduced in the Apple Watch Series 6 in 2020. It became particularly significant during the COVID-19 pandemic when monitoring blood oxygen levels became crucial. Apple is now making efforts to modify the algorithms on the device that measure a user's blood oxygen level. They are adjusting how the technology determines oxygen saturation and presents the data to customers.
If the ban is not overturned, it will take effect on December 25. Apple has already taken steps to prepare for the change by sending new signs to its retail outlets that promote the Apple Watch without showing photos of the Series 9 and Ultra 2 models.
Masimo has stated that a software fix will not be sufficient and that the hardware needs to change. The company believes that the ITC's judgment should be respected and that even the world's most powerful company must abide by the law.
To avert the ban, Apple can seek a settlement with Masimo or try to win favor with regulators by modifying its technology. Ultimately, the White House has the power to veto ITC decisions, as seen in a previous case involving a patent fight between Apple and Samsung Electronics. In this case, the decision would involve picking one US company over another, as Masimo is based in Irvine, California. The final decision will have significant implications for Apple's sales and reputation in its home country.
No comments:
Post a Comment